JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312015

Alexa Fluor® 555 Anti-DDAH1 antibody [EPR13922]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal DDAH1 antibody - conjugated to Alexa Fluor® 555.

View Alternative Names

DDAH, DDAH1, DDAH-1, Dimethylarginine dimethylaminohydrolase 1, DDAHI, Dimethylargininase-1

  • 578 PE

    PE Anti-DDAH1 antibody [EPR13922]

  • 660 APC

    APC Anti-DDAH1 antibody [EPR13922]

  • HRP

    HRP Anti-DDAH1 antibody [EPR13922]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-DDAH1 antibody [EPR13922]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-DDAH1 antibody [EPR13922]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-DDAH1 antibody [EPR13922]

  • 603 Alexa Fluor® 568

    Alexa Fluor® 568 Anti-DDAH1 antibody [EPR13922]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-DDAH1 antibody [EPR13922]

  • Unconjugated

    Anti-DDAH1 antibody [EPR13922]

  • Carrier free

    Anti-DDAH1 antibody [EPR13922] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR13922

Isotype

IgG

Conjugation

Alexa Fluor® 555

Excitation/Emission

Ex: 555nm, Em: 565nm

Carrier free

No

Applications

Target Binding Affinity, Antibody Labelling

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The DDAH1 protein also known as dimethylarginine dimethylaminohydrolase 1 plays an important role in regulating nitric oxide (NO) production by metabolizing asymmetric dimethylarginine (ADMA) an inhibitor of nitric oxide synthase. This enzyme has a molecular mass of approximately 31 kDa and is widely expressed in various tissues including liver kidney and brain. It impacts the cardiovascular system by controlling ADMA levels which influence endothelial function and vascular tone.
Biological function summary

The actions of DDAH1 contribute significantly to cardiovascular homeostasis. Increased levels of ADMA resulting from impaired DDAH1 activity can lead to decreased NO production impacting cardiovascular health. DDAH1 does not form part of a complex but acts individually to affect NO synthesis through ADMA degradation. Understanding the biological roles of DDAH1 helps to appreciate how NO-mediated processes are tightly regulated within the body and its impact on vascular health.

Pathways

DDAH1 participates actively in the nitric oxide synthesis pathway. It modulates the levels of endothelial nitric oxide synthase (eNOS) by regulating ADMA which serves as an eNOS inhibitor. Through this pathway DDAH1 ensures a balance between NO production and regulation supporting vascular homeostasis and blood pressure control. DDAH1 shares functional connections with proteins like eNOS which are central to maintaining vascular health and preventing endothelial dysfunction.

Dysfunction of DDAH1 links closely to cardiovascular diseases and conditions like atherosclerosis. Elevated ADMA levels resulting from compromised DDAH1 activity contribute to endothelial dysfunction a precursor to atherosclerosis. The interconnected role with eNOS highlights DDAH1's importance in managing ADMA concentrations as imbalances can exacerbate disease progression. Investigating the influence of DDAH1 on these diseases offers insights into potential therapeutic targets for cardiovascular pathologies.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation.
See full target information DDAH1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com